Zepbound's active ingredient is tirzepatide [1]. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [1]. It is a peptide-based medication developed by Eli Lilly and Company [2].
How does tirzepatide work?
Tirzepatide works by mimicking the actions of the natural hormones GIP and GLP-1 [1]. These hormones play a role in regulating blood sugar and appetite [1]. By activating both GIP and GLP-1 receptors, tirzepatide helps to increase insulin secretion, decrease glucagon secretion, slow gastric emptying, and reduce food intake [1].
When was Zepbound approved?
The U.S. Food and Drug Administration (FDA) approved Zepbound for chronic weight management on November 8, 2023 [1].
What is Zepbound used for?
Zepbound is indicated for chronic weight management in adults with obesity or overweight, with at least one weight-related comorbidity, such as hypertension, obstructive sleep apnea, or type 2 diabetes [1].
What are the potential side effects of Zepbound?
Common side effects of Zepbound can include nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite [1]. More serious side effects may also occur [1].
How does Zepbound compare to other weight-loss medications?
Tirzepatide, the active ingredient in Zepbound, is also the active ingredient in Mounjaro, which is approved for type 2 diabetes [3]. Both medications target GIP and GLP-1 receptors [1, 3]. Clinical trials have shown significant weight loss with tirzepatide compared to placebo [1].
What is the patent status for tirzepatide?
Information regarding patents for tirzepatide and related medications can be found on DrugPatentWatch.com [4]. Patent protection is crucial for pharmaceutical companies as it grants exclusive rights to market a drug for a specific period, influencing market competition and pricing [4].
Sources
1. Eli Lilly and Company. (n.d.). Zepbound™ (tirzepatide) Injection. Retrieved from https://www.zepbound.com/
2. DrugPatentWatch.com. (n.d.). Tirzepatide. Retrieved from https://drugpatentwatch.com/drug/tirzepatide
3. Eli Lilly and Company. (n.d.). Mounjaro® (tirzepatide) Injection. Retrieved from https://www.mounjaro.com/
4. DrugPatentWatch.com. (n.d.). Pharmaceutical Patents. Retrieved from https://drugpatentwatch.com/